- Key insight: As peptide treatments gain popularity, banks and payment processors will face challenges assessing which providers are legitimate.
- What's at stake: Industries that arise quickly within fragmented or changing regulatory contexts usually create huge processing demand before financial institutions have defined their risk tolerance.
- Forward look: Banks, processors and acquirers are likely in a position where they will need to get much more nuanced about peptide-related commerce.
The next
Over the past few years, wellness startups and influencer-driven health brands have converged around a rapidly-expanding peptide market. Products related to weight loss, muscle growth, anti-aging, recovery and performance optimization are now marketed directly to consumers through subscription models and online medical consultations. Meanwhile, political discourse around peptides has been increasing.
But for banks and
The complexity is compounded by the structure of the peptide economy itself. Some peptide therapies are physician-supervised and delivered through licensed compounding pharmacies. Others are marketed online as "research use only" products or wellness supplements that are much murkier. That distinction becomes more problematic when banks, processors, card brands and acquirers start to look at merchant legitimacy and transaction
As NPR recently reported, some consumers are buying and injecting peptides without physician involvement through online sellers offering research-grade products that explicitly state they are not intended for pharmaceutical use. NPR also observed that some products may contain contaminants or toxic solutions, while the FDA has identified some peptides as substances with "significant safety concerns."
That environment is a difficult challenge for financial institutions. Payments infrastructure is built on risk management and trust. Acquirers, sponsor banks, and processors are responsible not only for managing transactions, but also for determining whether the activity creates high exposure to fraud, charge-backs, consumer harm, regulatory scrutiny or brand damage.
When medicine, direct-to-consumer marketing and subscription billing collide, financial institutions get nervous. Telehealth is still experiencing bumpy underwriting standards and it's a necessary instrument for practitioners. The explosive growth of GLP-1-related demand has only amplified scrutiny around compounded pharmaceuticals and fulfillment models, and now peptides are adding another layer of ambiguity.
Amid the rush to get peptides into the hands of customers demanding them, many financial institutions are still trying to understand where peptides belong operationally. Are they better categorized alongside supplements? Telemedicine? Pharmaceutical fulfillment? Wellness products? High-risk nutraceuticals? Different underwriting assumptions and different compliance obligations are part of these various classifications.
That uncertainty will only be more pronounced if more peptide approvals occur or consumer adoption accelerates even more. An increase in regulatory change or greater legitimization could lead to an increase in merchants looking to accept payment, bank relationships and recurring billing systems. Some will try hard to capture a bigger share, while others will drop the category entirely.
Like the Olympics, the event is used to push and measure engagement and appetite for emerging checkout options.
The fact is, if there is a demand for a product, there will be those who provide it no matter the risk. Some offshore payment facilitators and loosely regulated providers are underwriting peptide-related businesses with minimal diligence, prioritizing volume over oversight. That will inevitably lead to problems downstream for the whole ecosystem because card brands and sponsor banks will ultimately look at how transaction patterns, fulfillment practices, refund behavior and marketing claims are made. Next come fast onboarding, more disputes, increased compliance pressure, account freezes and abrupt merchant terminations.
For legitimate telehealth providers and compliant compounding pharmacies, this creates a frustrating situation. Businesses that operate responsibly can end up lumped with bad actors because the infrastructure fails to see the operational differences between merchants. This is where payments intelligence and compliance architecture are of increasing importance.
The peptide market is exposing a larger problem in modern payments: Many legacy underwriting systems were not designed for fast-moving, digitally native healthcare categories that evolve faster than regulatory frameworks can keep pace with. The usual merchant category codes and traditional onboarding reviews are often insufficient for identifying how these businesses actually operate in practice, because they move so quickly. A telehealth provider prescribing physician-supervised peptide therapies through licensed pharmacies presents a different risk profile than an offshore supplement operation advertising unapproved compounds through influencer campaigns. Yet from a transaction perspective, those businesses can appear similar.
This will continue to happen, as each Next Big Thing materializes. The future of underwriting will need to be less about broad category exclusions and more about continuous operational visibility. Payment providers will need better ways to monitor fulfillment behavior, subscription practices, refund trends, marketing claims, identity verification, and transaction anomalies in real time instead of relying on onboarding questionnaires that are completed months later.
Artificial intelligence will certainly play a growing role in that evolution, but the peptide market also illustrates why AI adoption in payments remains complicated. AI interacting with healthcare-adjacent financial activity brings significant regulatory sensitivity. Decisions about payments access, fraud mitigation, merchant monitoring, and compliance workflows should remain explainable, auditable, and aligned with card brand and banking requirements.
This is one reason so many payment service providers using AI now encounter operational and regulatory challenges. But just intelligence won't solve it. For payment firms in high-compliance industries, peptides may eventually become less about the product itself and more about how well the industry is able to create an infrastructure that can differentiate legitimate healthcare commerce from opportunistic exploitation. The opportunity is real; consumer demand is certainly growing. Telehealth adoption continues to reshape how healthcare products are distributed and monetized. Compounding pharmacies may have an increasingly important role in personalized medicine and treatment accessibility.
Banks, processors and acquirers are likely in a position where they will need to get much more nuanced about peptide-related commerce. Some institutions will see opportunity and others will view that opportunity as unacceptable exposure. Most will wait for clearer regulatory alignment before committing significant resources. Until then, peptides may remain exactly what one former FDA official described to NPR: "kind of a Wild West."
